The Science of Enzyme Suppression: Why FGF23 Downregulates 1-Alpha Hydroxylase

Fibroblast growth factor 23 (FGF23) is a key hormone produced mainly by osteocytes in bone. Its primary role is to maintain phosphate and vitamin D balance. One of the most important actions of FGF23 is to suppress the renal enzyme 1-alpha hydroxylase (CYP27B1), which converts inactive vitamin D into its active form, 1,25-dihydroxyvitamin D. Understanding this interaction helps explain disorders like oncogenic osteomalacia, where abnormal FGF23 production leads to troubling mineral imbalances.

Vitamin D Metabolism in Brief

• 25-Hydroxylation (Liver)
  Dietary or skin-synthesized vitamin D (cholecalciferol) is first converted in the liver to 25-hydroxyvitamin D [25(OH)D]. This is the major circulating form and the best indicator of vitamin D status.

• 1-Alpha Hydroxylation (Kidney)
  In the kidney, CYP27B1 (1-alpha hydroxylase) transforms 25(OH)D into 1,25-dihydroxyvitamin D [1,25(OH)₂D], the active hormone that:

  • Increases intestinal calcium and phosphate absorption
  • Modulates bone remodeling
  • Influences immune function

• 24-Hydroxylation (Clearance)
  CYP24A1 inactivates both 25(OH)D and 1,25(OH)₂D, preventing vitamin D excess.

FGF23: The Phosphate-Regulating Hormone

FGF23 is secreted by bone cells in response to elevated phosphate, active vitamin D levels, or certain genetic signals. Its main effects are:

• Kidney Phosphate Wasting
  Reduces expression of sodium-phosphate co-transporters (NaPi-IIa and NaPi-IIc) in the proximal tubule, causing phosphate loss in urine.

• Vitamin D Suppression
  Lowers CYP27B1 activity and increases CYP24A1 expression, resulting in lower 1,25(OH)₂D levels.

How FGF23 Suppresses 1-Alpha Hydroxylase

1. Receptor Binding
   FGF23 binds to fibroblast growth factor receptors (FGFRs), primarily FGFR1, in the presence of the co-receptor α-Klotho on renal tubular cells.

2. Intracellular Signaling
   The FGF23–FGFR1–Klotho complex activates downstream pathways, including:

   • Mitogen-activated protein kinase (MAPK)
   • Extracellular signal-regulated kinase (ERK)

3. Gene Regulation

   • Decreases transcription of the CYP27B1 gene
   • Increases transcription of the CYP24A1 gene

4. Enzyme Activity Changes

   • Less CYP27B1 ⇒ Reduced conversion of 25(OH)D to 1,25(OH)₂D
   • More CYP24A1 ⇒ Accelerated breakdown of both 25(OH)D and 1,25(OH)₂D

The net effect is a drop in circulating 1,25(OH)₂D, which lowers intestinal phosphate absorption and further promotes phosphate excretion by the kidney.

Clinical Implications

Oncogenic Osteomalacia

Oncogenic (tumor-induced) osteomalacia is a rare paraneoplastic syndrome. Certain benign mesenchymal tumors overproduce FGF23, driving:

• Excessive phosphate loss in urine
• Suppression of 1-alpha hydroxylase ⇒ Low 1,25(OH)₂D
• Impaired bone mineralization ⇒ Bone pain, weakness, fractures

Although typical labs show low serum phosphate and low 1,25(OH)₂D, patients or clinicians searching “Serum 1,25 dihydroxyvitamin D high in oncogenic osteomalacia” may sometimes encounter confusing reports. It’s important to know that true oncogenic osteomalacia almost always involves low 1,25(OH)₂D levels, due to FGF23’s powerful enzyme suppression.

Other FGF23-Mediated Conditions

• X-linked hypophosphatemia
• Autosomal dominant hypophosphatemic rickets
• Chronic kidney disease (elevated FGF23 correlates with cardiovascular risks)

Signs, Symptoms, and When to Check

Common symptoms of FGF23 excess and resulting vitamin D deficiency include:

• Bone pain and muscle weakness
• Stress fractures or pseudofractures
• Difficulty walking or running
• General fatigue

If you experience ongoing bone pain, unexplained fractures, or persistent muscle weakness, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker.

Diagnosis

1. Blood Tests

   • Serum phosphate (low)
   • Serum calcium (usually normal or low-normal)
   • 25(OH)D (normal or low)
   • 1,25(OH)₂D (low)
   • FGF23 levels (elevated)

2. Urine Studies

   • Fractional excretion of phosphate (elevated)

3. Imaging for Tumor Localization

   • Functional imaging (octreotide scan, PET-CT)
   • MRI to pinpoint small mesenchymal tumors

Management Strategies

• Tumor Resection
  Complete surgical removal of the FGF23-producing tumor is often curative.

• Medical Therapy (if tumor can’t be found or resected)

  • Oral phosphate supplements
  • Active vitamin D analogs (calcitriol or alfacalcidol) to bypass the 1-alpha hydroxylase block
  • FGF23-blocking antibodies (for hereditary or refractory cases)

• Monitoring
  Regular checks of serum phosphate, calcium, and vitamin D metabolites guide dosing.

Key Takeaways

• FGF23 downregulates 1-alpha hydroxylase (CYP27B1) via FGFR1/Klotho signaling, reducing active vitamin D production.
• Low 1,25(OH)₂D drives less intestinal phosphate absorption, compounding renal phosphate wasting.
• Oncogenic osteomalacia features high FGF23, low phosphate, and low 1,25(OH)₂D—even though some sources may mistakenly mention elevated 1,25(OH)₂D.
• Early recognition and tumor removal can reverse the enzyme suppression and restore normal mineral balance.

If you suspect a serious mineral imbalance or have persistent bone pain and muscle weakness, please speak to a doctor as soon as possible.